Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EKA4
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EKA4 is a fully human monoclonal antibody (IgG4) that targets prostatic acid phosphatase (ACP3), a protein highly expressed in prostate epithelial cells and a clinically relevant antigen in prostate cancer. Developed using phage display technology from a naïve scFv library, EKA4 exhibits high affinity with a dissociation constant (KD) of 5 nM in its scFv format. It was subsequently cloned and expressed as a full-length IgG4 antibody in CHO cells. EKA4 is being investigated as a potential scaffold for the development of next-generation tumor-targeted therapeutics, particularly for patients with prostate cancer who do not benefit from PSMA-targeted therapies.
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on EKA4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EKA4.